Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 北京英诺特生物技术股份有限公司「连同其子公司合称“英诺特”」，下设英诺特（唐山）生物技术有限公司，是一家专注于POCT快速诊断产品研发、生产和销售的高科技生物医药企业，2022年7月28日在科创板上市（证券简称：英诺特，证券代码：688253）。公司以呼吸道病原体检测和多种病原体联合检测为特色，以急门诊，尤其是儿童急门诊检测作为切入点，致力于打造中国呼吸道病原体快速联合检测领导品牌。 英诺特生物创始于2006年，经过多年发展构建起了免疫层析、间接免疫荧光、液相免疫、核酸分子检测、基因重组蛋白工程及细胞和病原体培养6大技术平台。目前公司产品已覆盖呼吸道病原体、肠道病毒系列、肝炎等传染病系列、优生优育及性病等多个检测领域。 公司营销渠道覆盖全国各省区，并远销东南亚、中东、非洲、拉美、欧盟等海外地区。英诺特秉承以用户为中心的企业经营理念，为用户提供更准确、更便捷的产品和服务，用户的需求就是英诺特的追求。
Main Business POCT快速诊断产品研发、生产和销售
Legal Representative 张秀杰
Top Executives
董事长：叶逢光
董事：赵秀娟,Lin Yi,陈廷友,张晓刚,张秀杰
独立董事：胡天龙,孙健,谢幼华
Top 5 Shareholder
Shareholder name Nature Holding Date
鹰潭市余江区英斯盛拓企业管理中心限售股17.77%30/09/2024
鹰潭市余江区英斯信达企业管理中心（有限合伙）限售股11.05%30/09/2024
叶逢光限售股10.07%30/09/2024
鹰潭市余江区天航飞拓企业管理中心限售股9.19%30/09/2024
宁波梅山保税港区红杉智盛股权投资合伙企业（有限合伙）流通A股3.13%30/09/2024
Company Secretary 陈富康
Solicitors 北京市中伦律师事务所
Auditors 大信会计师事务所（特殊普通合伙）
Tel No 010-83682249-8029
Fax No 010-83682966
Website www.innovita.com.cn
Email ir@innovita.com.cn
Company Address
Register: 北京市丰台区海鹰路1号院6号楼1层2层
Office: 北京市丰台区海鹰路1号院6号楼1层2层
Listing Date 28/07/2022
Shares Capital
Shares Capital: 136,458,196
Total A Share: 136,458,196
Listed A Share: 68,810,680
Non-tradable A Share: 67,647,516
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.280
DPS(RMB)* ¥ 0.400
NBV Per Share(RMB)* ¥ 13.538
Market Capitalization(RMB) 2.901B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.